Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 685 matching trials from the live ClinicalTrials.gov search.
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide, R115777
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Malignant Glioma
Interventions
D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Interventions
Biospecimen Collection, Efineptakin alfa, Pembrolizumab, Biopsy
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Glioblastoma, Gliosarcoma
Interventions
Zactima, Gleevec, Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma
Interventions
M032, Pembrolizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Glioblastoma, Gliosarcoma
Interventions
Erlotinib and Dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Recurrent Glioblastoma, Recurrent High-grade Glioma
Interventions
Bicalutamide, Intensity-modulated radiation therapy (IMRT)
Drug · Radiation
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Brain Tumor, Astrocytoma, Astroglioma, Glioblastoma, Gliosarcoma
Interventions
Zotiraciclib (TG02), Temozolomide (TMZ)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Brain and Central Nervous System Tumors
Interventions
glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor, Anaplastic Oligoastrocytoma
Interventions
E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Duarte, California
Conditions
Recurrent Glioblastoma, Glioblastoma Multiforme, GBM
Interventions
5-ALA and Low-Intensity Focused Ultrasound (SDT)
Combination Product
Lead sponsor
Shayan Moosa, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Anaplastic Astrocytoma, Glioblastoma
Interventions
Sunitinib Malate
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Recurrent Glioblastoma
Interventions
Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab
Drug · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Glioblastoma
Interventions
CART-EGFR-IL13Ra2 Cells
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2039
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Recurrent Glioblastoma
Interventions
Sonication for opening of blood-brain barrier, Chemotherapy, albumin-bound paclitaxel, Chemotherapy, carboplatin
Device · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
Biological · Drug · Procedure
Lead sponsor
Hideho Okada, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma, Atypical Teratoid/Rhabdoid Tumor of Brain, Medulloblastoma, Ependymoma, Pleomorphic Xanthoastrocytoma of Brain, Embryonal Tumor of Brain
Interventions
Polio/Rhinovirus Recombinant (PVSRIPO)
Biological
Lead sponsor
Istari Oncology, Inc.
Industry
Eligibility
12 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 6 more
Conditions
Solid Tumors
Interventions
Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more
Conditions
RECURRENT GLIOBLASTOMA
Interventions
SGT-53, Temozolomide
Genetic · Drug
Lead sponsor
SynerGene Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, Recurrent Glioblastoma, Astrocytoma, Malignant, Astrocytoma of Brain
Interventions
Re-resection, Temozolomide, Lomustine, Re-irradiation, Experimental therapy, Best supportive care
Procedure · Drug · Radiation + 1 more
Lead sponsor
Jasper Gerritsen
Other
Eligibility
18 Years to 90 Years
Enrollment
464 participants
Timeline
2023 – 2028
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Conditions
Glioblastoma Multiforme
Interventions
ERAS-801
Drug
Lead sponsor
Katmai Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 5 more
Conditions
Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
Interventions
Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 7 more